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Abstract
Type 1 diabetes mellitus (DM), autoimmune thyroiditis (AIT), juvenile idiopathic arthritis (JIA), and inflammatory bowel
diseases (IBD) are common pediatric autoimmune diseases with unknown risk factors. Using nationwide registers, we searched
for their perinatal risk factors. Our study followed up 11,407 children (born 2000–2005) for a median of 16.6 years (from birth to
2018). Of them, 2.15% received primary diagnosis and 0.08% also secondary: 0.89% had DM, 0.60% had AIT, 0.48% had JIA,
and 0.25% had IBD. The incidences per 100,000 children/year were 106.1 for DM, 46.0 for AIT, 55.0 for JIA, and 23.7 for IBD.
There were more preterm births (< 37 weeks) among children with studied autoimmune diseases compared with the rest of the
cohort (8.6% vs. 5.3%, p = 0.035). Among those born preterm, children with studied autoimmune diseases received more
postnatal antibiotics compared with other preterm children in the cohort (47.6% vs. 27.7%, p = 0.046). Children with IBD were
born to older mothers compared with those without studied diagnoses (33.0 vs 30.2, p = 0.004).
Conclusion: Preterm birth was a shared risk factor for autoimmune diseases in our study, especially when combined with
postnatal antibiotic treatments. High maternal age was associated with IBD.
What is Known:
• Type 1 diabetes (DM), autoimmune thyroiditis (AIT), juvenile idiopathic
arthritis (JIA), and inflammatory bowel diseases (IBD) are common
pediatric autoimmune diseases
• It is unclear whether these diseases have shared risk factors, since there
are no previous simultaneous epidemiological nor follow-up studies
on them in one cohort
What is New:
• Preterm births were more common in children with DM, AIT, JIA, or
IBD compared with other children in the cohort, and preterm children
who developed these diseases recieved more postnatal antibiotics
compared with other preterm children
• High maternal age was associated with IBD
Keywords Autoimmune diseases . Environmental risk
factors .Maternal background . Perinatal conditions
Introduction
Autoimmune diseases are disorders, where the immune sys-
tem attacks normal tissues. In genetically susceptible individ-
uals, this could be triggered by environmental factors [1].
Genome-Wide Association Studies have uncovered multiple
predisposing genes that overlap between several autoimmune
diseases [2–4]. Yet, mutual environmental triggers have not
been identified—even when continuously increasing inci-
dence of these diseases (including those with pediatric onset)
may suggest their presence [5].
This study focuses on four common pediatric autoimmune
diseases: type 1 diabetes (DM), autoimmune thyroiditis (AIT),
juvenile idiopathic arthritis (JIA), and inflammatory bowel
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diseases (IBD). DM is a disorder of insulin secretion due to
destruction of β cells in the pancreatic islets of Langerhans by
autoreactive T cells, causing hyperglycemia [6–8]. AIT is a
disorder of thyroid hormone secretion due to T cell-mediated
attack on thyroid gland, causing hypothyroidism [9]. JIA is a
heterogeneous disease. Dysfunction of adaptive immune system
in oligo-/polyarticular JIA results in accumulation of activated T
cells in synovial membrane [10]. While oligo-/polyarticular JIA
stays in the joints, systemic JIA (presenting dysfunction of the
innate immune system) could affect extrasynovial tissues as
well, eliciting symptoms like spiking fever, rash, serositis,
lymphadenopathy, and hepatosplenomegaly [11]. IBD are
chronic autoimmune inflammations of gastrointestinal tract, in-
volving T cell infiltration in the gut mucosa [12]. There are two
main IBD subtypes: Crohn disease (CD) and ulcerative colitis
(UC) [13, 14]. CD causes transmural inflammation and may
involve any part of the gastrointestinal tract, while UC causes
mucosal inflammation and is limited to the colon. When varia-
tions in the location, nature, and severity of inflammation in the
colon are present, the term IBD unclassified (IBDU) is used
[15].
Since DM, AIT, JIA, and IBD have similar characteristics,
such as (1) overlapping genetic associations, (2) chronic and
usually intermittent inflammation, (3) involvement of T cell
organ infiltrations, and (4) increasing incidence without spe-
cific triggering factors, we assumed that theymay havemutual
environmental risk factors. This study aims to search for these
risk factors right from the beginning—among maternal and
perinatal backgrounds.
Methods
Data sources and study population
This register-based cohort study was conducted among partic-
ipants of Finnish Health in Teens (Fin-HIT) study. The na-
tionwide Fin-HIT cohort was assembled mostly by school
recruitments in vast, densely populated areas throughout
Finland without specific exclusion criteria. In total, 11,407
children (52.2% girls) born between 2000 and 2005 partici-
pated. Their families eligibly represented general population,
even when the parent’s education level was relatively high.
More details on recruitment and characteristics of the cohort
were described elsewhere [16]. The frequency of DM, AIT,
JIA, and IBD and their possible maternal and perinatal risk
factors were studied by linking the cohort to three national
health registers: Medical Birth Register (MBR), Special
Reimbursement Register (SRR), and Drug Purchase Register
(DPR). The excellent coverage of these registers has been
described previously [17]. MBR held by the Finnish
Institute for Health and Welfare (THL) provides information
on maternal backgrounds (employment status before delivery,
smoking habit, age, parity, and delivery method) and perinatal
factors (birthweight, height, gestational length, postnatal anti-
biotic treatment, and inpatient length of stay) [18]. MBR was
successfully linked to 11,380 children. Of them, 10,944 had
available maternal and perinatal information.
Identification of patients with chronic immune-
mediated diseases in the cohort
Each Finnish resident has a personal identifier number.
Every register linkage is based on this, including SRR
and DPR maintained by the Finnish Social Insurance
Institution [17, 19]. SRR contains records on patients with
chronic diseases necessitating medications, who are enti-
tled to drug refunds (i.e., special reimbursements) regard-
less of their socioeconomic status. These records include
diagnoses (verified by physicians according to standard-
ized criteria) and entry dates. DPR lists all purchases of
prescribed medications, including dispensation dates and
pharmaceutical information [17].
DM, JIA, and IBD diagnoses in the cohort (from birth until
31 December 2018) were obtained using ICD-10 codes
(International Classification of Diseases (ICD), 10th revision)
from SRR (E10.9 for DM; M08 for JIA; K50 (CD) and K51
(UC/IBDU) for IBD). AIT diagnoses were obtained from
DPR using ATC (Anatomical Therapeutic Chemical) code
H03AA01 for thyroxin—the only drug used for AIT, which
is available on prescription only. DPR was chosen for identi-
fying AIT because thyroxin is inexpensive and not everyone
applies for the special reimbursement/is registered in SRR.
Statistical methods
The data were analyzed through two perspectives. (1)
Patients: when studied autoimmune diseases were observed
concurrently, secondary diagnoses were ignored and the index
group comprised all individuals with studied autoimmune dis-
eases (N = 245). (2) Diagnoses: when each diagnosis (DM,
AIT, JIA, or IBD) were observed individually, secondary di-
agnoses were considered, comprising 254 cases. When esti-
mating the peak incidence of the studied autoimmune dis-
eases, the study population was divided into three groups
based on children’s physical developmental stages and corre-
sponding usual daytime environment: infancy to preschool
age (0–5.9 years in daycare), pre-pubertal age (6–11.9 years
in primary school), and adolescence (12–18 years in second-
ary school).
Categorical variables were tested using Chi-square (χ2) or
Fischer’s exact test. Continuous variables were tested using
Independent sample t test or Kruskal-Wallis test. The data are
displayed with number and proportion (%), mean and stan-
dard deviation (SD), or median and interquartile range (IQR).
When the size and proportion of the cohort were regarded,
2116 Eur J Pediatr (2021) 180:2115–2123
95% confidence interval (CI) was presented withWilson score
interval. The software used was IBM SPSS Statistics 26.0 and
a 5% statistical significance level was adopted.
Results
The cohorts of 11,407 children born in 2000–2005 were
followed-up from birth until 31 December 2018. Their end-
point median age was 16.6 years (IQR 14.6–18.6). Of them,
245 children (2.1%) received at least one diagnosis: 102
(0.89%) were diagnosed with DM, 68 (0.60%) with AIT, 55
(0.48%) with JIA, and 29 (0.25%) with IBD (UC 19 (0.17%)
and CD 10 (0.09%)) (Table 1). Only 9 children out of 245
(0.08% of the whole cohort) were presented with multiple
diagnoses—7 had DM and AIT, 1 had AIT and JIA, and 1
had DM and IBD—comprising 254 diagnoses.
Of the four diagnoses, DM had the highest incidence
(106.1/100,000 children/year) and IBD had the lowest (23.7;
UC 16.3 and CD 7.5) (Table 1). AIT had the oldest median
age of diagnosis (13.9 years, IQR 11.1–15.8), while DM had
the youngest (8.6 years, IQR 4.8–11.9). DM and JIA emerged
equally in different age groups (Fig. 1, Supplement Table 1).
By contrast, AIT was significantly highest during adoles-
cence, reaching 64.5 (95% CI 48.1–86.5), lower in pre-
pubertal age (30.8; 95% CI 20.1–48.1), and lowest in pre-
school age (4.4; 95% CI 1.5–12.9). The peak incidence of
IBD was also seen during adolescence with 20.5 (95% CI
12.2–34.4), but the difference was not prominent compared
with other age groups: 16.1 (95% CI 9.0–28.9) for pre-
pubertal age and 5.9 (95% CI 2.3–15.1) for preschool age.
DM was more common in boys, in contrast to AIT and JIA
(Fig. 2, Supplement Table 2). IBD were equally distributed
between both sexes.
Children with studied autoimmune diseases experienced
more preterm births (born < 37 weeks) than the rest of the
cohort (8.6% vs. 5.3%, p = 0.035) (Table 2). Of all preterm
children in the cohort (N = 614), 42.7%were born by cesarean
section (15.4% in full term, p < 0.001) and 28.3% received
postnatal antibiotics (3.2% in full term, p < 0.001).
Furthermore, preterm children born by cesarean section (N =
262) received more postnatal antibiotics compared with pre-
term children born by vaginal delivery (55.2% vs. 44.8%, p <
0.001), implying for a potential link between preterm birth,
cesarean section, and early antibiotic use in general.
When focusing on preterm children only (N = 614), most
maternal and perinatal factors were similar in those who de-
veloped studied autoimmune diseases and in those who did
not (Supplement Table 3a). Birth by cesarean section was also
as common in those who developed studied autoimmune dis-
eases and in other preterm children (47.6% vs. 42.5%, p =
0.581) (Supplement Table 3a). In contrast, preterm children
who developed studied autoimmune diseases received postna-
tal antibiotic treatments more frequently compared with other
preterm children (47.6% vs. 27.7%, p = 0.046). This finding
was seen only in concurred analysis of the studied autoim-
mune diseases and was not associated with any particular
autoimmune diagnosis (Supplement Table 3b). In full term
children (born ≥ 37 weeks), postnatal antibiotic treatments
were equally low in children who developed autoimmune dis-
eases and in those who did not (2.1% vs. 1.8%, p = 0.692).
The mothers of IBD children had higher maternal age com-
pared with the mothers of children without studied autoim-
mune diseases (33.0 vs 30.2 years, p = 0.004). Other maternal
and perinatal factors were similar in children with any of the
studied autoimmune diseases and in those without these
diseases.
Discussion
Our study is the first to describe the simultaneous prevalence
of DM, AIT, JIA, and IBD in a pediatric cohort. The 11,407
children in our study covered 3.5% of all Finnish children
born in 2000–2005 [20]. After a median follow-up of 16.6
years, 2.1% obtained above diagnoses—mostly established
Table 1 Prevalence, incidence
per 100,000 children/year, and
median age of diagnosis of
pediatric onset DM,AIT, JIA, and
IBDa. The 11,407 children in the
cohort were born in 2000–2005
and follow-upwas continued until
a median age of 16.6 years. Of
them, 245 received primary diag-




(2.23% of total cohort)
Incidence/100,000 children/year
(95% CIb)
Median age of diagnosis
(IQRc)
DM 102 (0.89%) 106.1 (87.5–128.6) 8.6 (4.8–11.9)
AIT 68 (0.60%) 46.0 (36.3–58.2) 13.9 (11.1–15.8)
JIA 55 (0.48%) 55.0 (42.3–71.6) 9.0 (4.4–12.9)
IBD 29 (0.25%) 23.7 (16.5–34.0) 11.6 (8.3–13.6)
a Abbreviations: DM type 1 diabetes mellitus, AIT autoimmune thyroiditis, JIA juvenile idiopathic arthritis, IBD
inflammatory bowel diseases
b Confidence interval using Wilson score interval
c Interquartile range
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at the age of 12–18 years (especially AIT and IBD). These
children experienced more preterm births (< 37 weeks) com-
pared with the rest of the cohort (8.8% vs. 5.6%).
Furthermore, among those born preterm, more frequent use
of postnatal antibiotics was associated with above autoim-
mune diseases.
The frequencies of many pediatric onset autoimmune dis-
eases have been escalating especially in the western world.
Finland is no exception. While the incidence of DM in
Sweden, Norway, and UK-Northern Ireland were over 30.0
in 2009–2013, in our study (2000–2018) it reached up to
106.1/100,000 children/year [21]. The prevalence of AIT in
our study was 0.60%—over four times higher than in Scotland
(1993–1995), with 0.135% for individuals under 22 years
[22]. Furthermore, our incidence of pediatric AIT was
46.0—almost three times higher than in a Spanish study
(2010–2016) with 16.7 in children under 15 years [23]. As
for JIA, the incidence in our study was 55.0, higher than in
previous decades (19.5 in 1995) [24]. JIA incidence in other
Scandinavian countries (1997–1999) ranged between 7 and
23, and in USA (1996–2006) it was 11.9 [25, 26]. The situa-
tion with IBD is also worrisome. Continuous increase of IBD
incidence in children has been reported especially in northern
Europe and North America [27, 28]. In our study, the inci-
dence of IBD was 23.7 (16.3 for UC and 7.5 for CD), which
corresponded to previous Finnish study presenting increased
incidence from 7.0 in 1987–1990 to 23 in 2011–2014 [29]. In
other Scandinavian countries, the annual incidence of pediat-
ric IBD in Norway (2005–2007) was 10.9 (CD 6.8 and UC
3.6) and in Sweden (2002–2007) was 12.8 (CD 9.2 and UC
2.8) [30, 31]. Unexpectedly, Finland had the highest incidence
of all four studied autoimmune diseases.
To plan effective preventive strategies, it is necessary to
identify shared environmental risk factors for pediatric auto-
immune diseases above. While searching for these risk factors
among perinatal backgrounds, we discovered that preterm
birth was a shared risk factor. Throughout Finland, 6.0% were
born preterm in 2000–2005 [32]. Even though preterm birth in
our study was not directly associated with any particular au-
toimmune disease, the highest preterm frequency (13.7%) was
observed in patients with IBD. This corresponded with previ-
ous study associating preterm births with the onset of IBD
later in life [33]. Preterm births have been associated with
the development of DM, AIT, and JIA as well [34–37].
Despite that many studies have successfully related preterm
birth and individual autoimmune diseases above, none of
them have studied them simultaneously. Therefore, our find-
ings implied that preterm birth might be a risk factor for auto-
immune diseases in general and not limited only to certain
diseases.
The potential mechanism relating preterm birth and auto-
immune diseases can be speculated. Preterm children gener-
ally received more postnatal antibiotics compared with full-
term children (28.3% vs. 3.2% in our study), which we have
presented as a potential risk factor. In addition, preterm birth
may deprive neonates from influences of intrauterine factors
such as maternal antibodies and placenta-derived elements,
while prematurely exposing them to extrauterine factors such




























Fig. 1 Incidence of pediatric
onset DM, AIT, JIA, and IBDa
per 100,000 children per year
with upper 95% CI. The children
were born in 2000–2005 and
follow-up was continued until a
median age of 16.6 years.
Legend: ■ = 0–5.9 years, ■ = 6–
11.9 years, ■ = 12–18 years. a
Abbreviations: DM = type 1 dia-
betes mellitus, AIT = autoim-
mune thyroiditis, JIA = juvenile
idiopathic Arthritis, IBD =
Inflammatory bowel diseases













Fig. 2 Sex distribution of DM, AIT, JIA, and IBDa per 100,000 children
per year with upper 95% CI. The children were born in 2000–2005 and
follow-up was continued until a median age of 16.6 years. Legend: ■ =
total, ■ = boys, ■ = girls . a Abbreviations: DM = type 1 diabetes mellitus,
AIT = autoimmune thyroiditis, JIA = juvenile idiopathic arthritis, IBD =
inflammatory bowel diseases
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as microbiota and nutritional antigens [38]. Together, these
may alter the development of immune responses and suscep-
tibility to autoimmune diseases. Moreover, maternal autoim-
mune diagnosis may induce preterm birth, as seen in case of
IBD [39]. However, in our study, maternal diagnoses were not
available.
Preterm birth might also connect autoimmune diseases and
highmaternal age. Despite that maternal age seemed unrelated
to autoimmune diseases in our study, further observation re-
vealed that the mothers of children with IBD were on average
3 years older at delivery (33.0) compared with the mothers of
children without studied autoimmune diseases (30.2). Similar
Table 2 Frequency of DM,AIT, JIA, and IBDa in relationwithmaternal backgrounds, delivery method, and perinatal factors. Of 11,407 children in the
















Maternal employment status (%) 0.655b
- Upper-level employees 35 (34.3) 13 (19.1) 14 (25.5) 10 (34.5) 71 (29.0) 3096 (27.8)
- Lower-level employees 38 (37.2) 33 (48.5) 20 (36.4) 10 (34.5) 97 (39.6) 4199 (37.7)
- Manual and self-employed workers 9 (8.8) 7 (10.3) 10 (18.2) 4(13.8) 28 (11.4) 1375 (12.3)
- Students 6 (5.9) 7 (10.3) 6 (10.9) 3 (10.3) 21 (8.6) 1106 (9.9)
- Housewives 7 (6.9) 4 (5.9) 4 (7.3) 2 (6.9) 17 (6.9) 628 (5.6)
- Unemployed, pensioners 0 1 (1.5) 0 0 1 (0.4) 31 (0.3)
- Missing data 7 (6.9) 3 (4.4) 1 (1.8) 0 10 (4.0) 701 (6.3)
Mother’s smoking habit (%) 0.825b
- Not smoking 87 (85.3) 59 (86.8) 49 (89.1) 26 (89.7) 213 (86.9) 9333 (83.8)
- Quitted during 1st trimester 3 (2.9) 1 (1.5) 2 (3.6) 0 6 (2.4) 190 (1.7)
- Smoked after 1st trimester 7 (6.9) 7(10.2) 2 (3.6) 2 (6.9) 17 (6.9) 835 (7.5)
- Missing data 5 (4.9) 1 (1.5) 2 (3.6) 1 (3.4) 9 (3.7) 778 (7.0)
Maternal age, mean ± SD 31.0 ± 5.3 30.5 ± 5.3 29.8 ± 5.5 33.0 ± 5.1c* 30.9 ± 5.3 30.2 ± 5.2 0.480c
- Missing data (%) 2 (2.0) 1 (1.5) 0 0 3 (1.2) 471 (4.2)
Children’s birth year (%) 0.316b
- 2000 16 (15.7) 14 (20.6) 9(16.4) 3(10.3) 41 (16.7) 1587 (14.3)
- 2001 24 (23.5) 20 (29.4) 8(14.5) 10 (34.5) 59 (24.1) 2498 (22.4)
- 2002 31 (30.4) 29 (42.6) 24 (43.6) 10 (34.5) 90 (36.7) 3513 (31.5)
- 2003 9 (8.8) 2 (2.9) 8(14.5) 2 (6.9) 20(8.2) 1038(9.3)
- 2004 10(9.8) 1 (1.5) 4 (7.3) 4(13.8) 19(7.8) 1190 (10.7)
- 2005 10(9.8) 1 (1.5) 2 (3.6) 0 13(5.3) 851 (7.6)
- Missing data 2 (2.0) 1 (1.5) 0 0 3 (1.2) 458 (4.1)
Parity, median 1 1 1 1 1 1 0.540d
(IQR) (0–2) (0–2) (0–2) (0–3) (0–2) (0–2)
(Range) (0–3) (0–4) (0–11) (0–6) (0–11) (0–14)
- Missing data (%) 3 (2.9) 1 (1.5) 0 0 4 (1.6) 477 (4.3)
Delivery method (%) 0.430b
- Normal vaginal delivery 77 (75.5) 53 (77.9) 45 (81.8) 19 (65.5) 186 (75.9) 8125 (73.0)
- Forceps or vacuum extraction 3 (2.9) 5 (7.4) 3 (5.5) 3 (10.3) 14 (5.7) 710 (6.4)
- Cesarean section 19 (18.6) 9(13.2) 7(12.7) 7 (24.1) 41 (16.7) 1805 (16.2)
- Missing data 3 (2.9) 1 (1.5) 0 0 4 (1.6) 496 (4.5)
Birthweight (g), mean ± SD 3471 ± 573 3393 ± 575 3394 ± 593 3553 ± 628 3440 ± 590 3515 ± 559 0.993c
- Missing data (%) 3 (2.9) 1 (1.5) 0 0 4 (1.6) 474 (4.3)
Birth height (cm), mean ± SD 49.9 ± 2.8 49.8 ± 2.5 49.9 ± 2.9 50.5 ± 2.8 49.9 ± 2.7 50.2 ± 2.5 0.905c
- Missing data (%) 3 (2.9) 1 (1.5) 0 0 4 (1.6) 507 (4.6)
Length of gestation (%) 0.035b
- ≥ 37 weeks 90 (88.2) 63 (92.6) 50 (90.9) 25 (86.2) 219 (89.4) 10,044 (90.2)
- < 37 weeks 9 (8.8) 4 ( 5.9) 4 (7.3) 4(13.8) 21 (8.6) 593 (5.3)
- Missing data 3 (2.9) 1 (1.5) 1 (1.8) 0 5 (2.0) 499 (4.5)
Postnatal antibiotic treatments (%) 5 (5.4) 3 (4.5) 5 (9.1) 3 (10.3) 16 (6.6) 487 (4.6) 0.135b
- Missing data 2 (2.0) 1 (1.5) 0 0 3 (1.2) 471 (4.2)
Inpatient length of stay (days), median (range) 3 (1–39) 3 (2–12) 3 (2–9) 3 (2–7) 3 (1–39) 3 (0–71) 0.978d
- Missing data (%) 3 (2.9) 1 (1.5) 0 0 4 (1.6) 479 (4.3)
aDM = type 1 diabetes mellitus, AIT = autoimmune thyroiditis, JIA = juvenile idiopathic arthritis, IBD = inflammatory bowel diseases
b Chi-square test for children with primary diagnoses and without diagnoses
c Independent sample t test for children with primary diagnoses and without diagnoses
c*When compared with children without diagnoses using independent sample t test, p = 0.004
dKruskall-Wallis H test for children with primary diagnoses and without diagnoses
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finding has been presented previously at least for Crohn dis-
ease [40]. A Swedish medical birth register study showed that
older mothers were more prone to preterm delivery [41]. In
Finland, mean maternal age was 27.6 years in 2000 and 30.0
years in 2005, but the percentage of preterm birth has not been
increasing (6.3% in 2000 and 5.7% in 2005) [32, 42]. In the-
ory, high maternal age could be related to IBD via preterm
birth, but on the other hand, since there were only 29 children
with IBD in our study, it is possible that our finding on ma-
ternal age, though significant, was a coincidence.
The link between autoimmune diseases and cesarean sec-
tion has been studied previously with ambiguous findings [43,
44]. In line with other studies on DM and IBD, we showed
that cesarean section itself was not a risk factor for studied
autoimmune diseases in full term nor in preterm children
[44–47]. Instead, preterm children born by cesarean section
received more postnatal antibiotics than preterm children born
by vaginal delivery. This, the use of postnatal antibiotics in
preterm children born by cesarean section rather than the ce-
sarean section itself, was more tightly associated with the on-
set of autoimmune diseases—potentially explaining some of
the ambiguous findings in previous studies. In fact, we dem-
onstrated that preterm children who later developed DM, AIT,
JIA, or IBD received 1.7-time more postnatal antibiotics com-
pared with preterm children without these diseases. Even
though our study did not confirm the role of postnatal antibi-
otic treatment as a risk factor for studied autoimmune diseases
in full term children, it has been shown to modulate neonate’s
gut microbiota [48]. Conclusively, postnatal antibiotic treat-
ments and other preterm-related factors (gut immaturity, intra-
uterine infection, maternal antibiotics, type of early feeding,
etc.) could influence the composition of gut microbiota in
preterm neonates and predispose dysbiosis [49]. It is uncer-
tain, whether (such) dysbiosis during neonatal period might
extend beyond early childhood and associate with the onset of
DM, AIT, JIA, and/or IBD [50–55]. Therefore, long-term
studies on gut microbiome involving pre-diagnostic phase of
these autoimmune diseases are warranted.
In our cohort, high maternal employment and low percent-
age of maternal smoking (7.5%) corresponded to previous
reports [56, 57], and most importantly, were similar for all
children. These aspects preclude the estimation of how heavy
maternal smoking and/or lower socioeconomic status, often
intertwining with one another, would relate to the develop-
ment of autoimmune diseases. Previous studies relating intra-
uterine exposure to smoking and autoimmune diseases have
presented various results as well [58–61]. However, these
studies have not always considered the role of preterm birth,
which was more common among smoking women [62].
The strength of our study lies in the coverage of the cohort
and the comprehensive data on the national registers.With high
worldwide incidence of pediatric autoimmune diseases,
Finland is an eligible representative for studies on their
environmental risk factors. Our study population was vastly
distributed throughout the country, enclosing all densely pop-
ulated areas. Furthermore, the registration coverage of the
Finnish public health system is exceptional. All chronic auto-
immune diseases are diagnosed and treated in the public sec-
tors, and utilized data are submitted to nationwide registers with
confirmed validity [17]. By using these registers, our data was
assured to be comprehensive. Nevertheless, since our data was
mostly obtained from densely populated regions, comparison
between urban and rural areas was unfeasible—this was one of
our limitations. Moreover, ethnic variations in Finland are very
small, andmost residents are highly educated. This is especially
true concerning parents in our cohort, which implies a possible
bias toward participants from families with high education level
[16]. Lack of diversity in social background of our study pop-
ulation may limit observations on certain risk factors related to
it such as socioeconomic status, smoking habits, and role of
ethnical backgrounds. Other limitation concerns variations in
the children’s age at the end of follow-up. This might especially
influence AIT, which peak incidence occurred at later age than
other studied autoimmune diseases.We estimated that the num-
ber of new AIT cases would have increased slightly if all chil-
dren had been followed until the age of 18, resulting to AIT
incidence of 50.2, but this did not alter our conclusion about it.
Finally, we focused only on four pediatric autoimmune dis-
eases. Celiac disease has a known triggering factor (gluten)
and requires no long-term medical prescriptions, thus was not
available in SRR [63]. Asthma was excluded due to different
criteria for receiving special reimbursement (a previous non-
stop medical treatment of minimum 6 months is required), and
many infants outgrow their obstructive symptoms and the need
for medications.
Conclusion
We have discovered that preterm birth and postnatal antibiotic
use associated with it are related to typical pediatric onset au-
toimmune diseases (DM, AIT, JIA, and IBD. These perinatal
factors were not related to any particular disease, hence could
be a shared risk factor. Furthermore, high maternal age was
related to IBD. Our findings may provide partial explanation
for the high incidence of these pediatric autoimmune diseases,
but further studies are required to focus on possible mecha-
nisms in details, such as the stability of neonatal gut dysbiosis.
Abbreviations AIT , Autoimmune thyroiditis; ATC, Anatomical thera-
peutic chemical; CD, Crohn disease; DM, Type 1 diabetes; DPR, Drug
purchase register; IBD , Inflammatory bowel diseases; IBDU,
Inflammatory bowel diseases unclassified; IQR, Interquartile range;
JIA, Juvenile idiopathic arthritis; MBR, Medical Birth Register; SD,
Standard deviation; SRR, Special Reimbursement Register; UC,
Ulcerative colitis
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